Jakavi approved in Korea

Published: 2013-02-07 06:58:00

Updated: 2013-02-07 06:58:00

Novartis Korea has recently received approval from the Korea Food and Drug Administration for Jakavi (INC424, ruxolitinib tablets), a drug for the treatment of disease-related splenomegaly and/or its associated symptoms in adult patients with myelofibrosis (MF), a blood cancer.1 Jakavi is the fir...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK